In the European Union<unk>  is indicated for the treatment of urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma, and breast cancer. In the United States,<unk>  is indicated for the treatment of urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and melanoma.
Atezolizumab
Tocilizumab
Ixekizumab
Caplacizumab
Satralizumab
Risankizumab
Bimekizumab
Benralizumab